Corrections · November 8, 2026
Email weightlossglpone@gmail.com with the page, the statement and a source. We check corrections against first-party sources, fix the page, change its review date only when its content changes, and log material corrections below with the date.
How we handle corrections
- We read the source you send and the program’s own page.
- If we were wrong, we fix the page and record the change here.
- Price changes are dated on the page; older prices stay visible under a dated heading or notice.
Corrections log
| Date | Pages | Correction |
|---|---|---|
| November 8, 2026 | Sitewide | Withdrew the description of the site as an "independent" review desk and statements that commissions never influence scoring or placement; replaced the per-page disclosures with one footer disclosure naming the affiliate relationship. |
| November 8, 2026 | Sitewide | Pages had credited Eduard Cristea as author and Dr. A. Goher, MD (with other named reviewers) as medical reviewers. Pages now credit Dr. Parmis (research) and Dr. Jonathan Snipes, MD and Kim Callender, NP (FNP-BC) (medical review). |
| November 8, 2026 | Sitewide | Removed claims about NexLife that its own pages do not support: MD/DO or board-certified clinicians, labs included, six 503A and 503B partner pharmacies, LegitScript certification and Trustpilot ratings. NexLife’s plan pages name three state-licensed 503A pharmacies. |
| November 8, 2026 | Sitewide | Updated NexLife prices to its November 6, 2026 change ($129 / $115 tirzepatide, $109 / $95 semaglutide) and removed statements implying NexLife is the cheapest option; programs with lower prices are named on the price pages. |
| November 8, 2026 | Homepage and sitewide | Removed the "live" price ticker (its percentage changes were not sourced) and an unattributed reader quote. |
| November 8, 2026 | Medicare pages | Corrected the Medicare GLP-1 Bridge description: it covers Foundayo, Wegovy and the Zepbound KwikPen only (not vials), runs July 1, 2026 to December 31, 2027, and excludes people with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease. |
| November 8, 2026 | Methodology | Replaced the six-pillar rubric with the v4.1 methodology; other programs’ July 2026 scores are labelled as such until re-scored. |